Aptose Biosciences Inc. (NASDAQ:APTO) Q2 2020 Earnings Conference Call - Final Transcript
Aug 04, 2020 • 05:00 pm ET
Good afternoon. My name is Victor, and I will be your conference operator today. I would like to welcome everyone to the Aptose Biosciences conference call for the second quarter ended June 30, 2020. [Operator Instructions] Thank you. As a reminder, this conference call may be recorded. I would now like to introduce Ms. Susan Pietropaolo. Please go ahead.
Susan M. Pietropaolo
Thank you, Victor. Good afternoon, and welcome to the Aptose Biosciences conference call to discuss financial and operational results for the second quarter ended June 30, 2020. I'm Susan Pietropaolo, a communications representative for Aptose Biosciences. Joining me on the call today are Dr. William G. Rice, Chairman, President and CEO; Mr. Gregory Chow, Executive Vice President and Chief Financial Officer; Dr. Jotin Marango, Senior Vice President and Chief Business Officer; and Dr. Rafael Bejar, Senior Vice President, Chief Medical Officer.
Before we proceed, I would like to remind everyone that certain statements made during this call will include forward-looking statements within the meaning of U.S. and Canadian securities laws. Forward-looking statements reflect Aptose's current expectations regarding future events but are not guarantees of performance, and it is possible that actual results and performance could differ materially from these stated expectations.
They involve known and unknown risks, uncertainties and assumptions that may cause actual results, performance and achievements to differ materially from those expressed. To learn more about these risks and uncertainties, please read the risk factors set forth in Aptose's most recent annual report on Form 10-K and SEC and SEDAR filings. All forward-looking statements made during this call speak only as of the date they are made. Aptose undertakes no obligation to revise or update the statements to reflect events or circumstances after the date of this call, except as required by law. I will now turn the call over to Dr. Rice, Chairman, President and CEO of Aptose Biosciences. Dr. Rice.
William G. Rice
Thank you, Susan. I'd like to welcome everyone to our call for the second quarter ended June 30, 2020. Separately, I do hope that all of you and your loved ones are safe from COVID, and I hope that all of you on the East Coast, in particular, are safely weathering the tropical storm. So please do take care. And now back to Aptose. As you're aware, Aptose is developing 2 distinctive clinical assets: first, we have CG-806, which has become a high profile, first-in-class FLT3 and BTK kinase inhibitor; and second is APTO-253, the only known clinical-stage agent that directly targets the MYC oncogene and suppresses its expression.
Before I bring you up-to-date on both clinical assets, let me note that we remain firmly bullish on CG-806, and we understand the primary importance of successfully executing our clinical plan for 806. And indeed, we are executing on the original plan to first develop 806 for patients with chronic lymphocytic leukemia or CLL and other B-cell malignancies, to observe inhibition of BTK and lymphocytosis in CLL patients and to be on track to reach higher dose levels and